A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients
A 6-Month, Randomized, Double-Masked Comparison Of Fixed Combination Of Latanoprost And Timolol With The Individual Components, Continuing Into A 6-Month Open Label Safety Study Of Fixed Combination In Patients With Glaucoma Or Ocular Hypertension.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Aachen, Germany
- Pfizer Investigational Site
-
Aalen, Germany
- Pfizer Investigational Site
-
Ahaus, Germany, 48683
- Pfizer Investigational Site
-
Alzey, Germany, 55232
- Pfizer Investigational Site
-
Aschaffenburg, Germany, 63739
- Pfizer Investigational Site
-
Bad Abbach, Germany, 93077
- Pfizer Investigational Site
-
Berlin, Germany, 13088
- Pfizer Investigational Site
-
Coesfeld, Germany, 48653
- Pfizer Investigational Site
-
Dillingen, Germany, 89407
- Pfizer Investigational Site
-
Eitorf, Germany, 53783
- Pfizer Investigational Site
-
Erlangen, Germany, 91052
- Pfizer Investigational Site
-
Essen, Germany, 45147
- Pfizer Investigational Site
-
Freiburg, Germany, 79106
- Pfizer Investigational Site
-
Freising, Germany, 85354
- Pfizer Investigational Site
-
Fulda, Germany
- Pfizer Investigational Site
-
Greifswald, Germany, 17489
- Pfizer Investigational Site
-
Gummersbach, Germany, 51643
- Pfizer Investigational Site
-
Hannover, Germany
- Pfizer Investigational Site
-
Hirschaid, Germany, 96114
- Pfizer Investigational Site
-
Iserlohn, Germany, 58638
- Pfizer Investigational Site
-
Koblenz, Germany, 56068
- Pfizer Investigational Site
-
Leonberg, Germany, 71229
- Pfizer Investigational Site
-
Leverkusen, Germany, 51373
- Pfizer Investigational Site
-
Mainz, Germany, 55116
- Pfizer Investigational Site
-
Mainz, Germany, 55124
- Pfizer Investigational Site
-
Mainz, Germany, 55131
- Pfizer Investigational Site
-
Muenchen, Germany, 80336
- Pfizer Investigational Site
-
Muenchen, Germany, 81925
- Pfizer Investigational Site
-
Mülheim, Germany, 45481
- Pfizer Investigational Site
-
Münster, Germany, 48165
- Pfizer Investigational Site
-
Offenbach, Germany, 63065
- Pfizer Investigational Site
-
Osnabrueck, Germany, 49076
- Pfizer Investigational Site
-
Parsberg, Germany, 92331
- Pfizer Investigational Site
-
Siegburg, Germany, 53721
- Pfizer Investigational Site
-
Sulzbach, Germany, 66280
- Pfizer Investigational Site
-
Trier, Germany, 54290
- Pfizer Investigational Site
-
Weiden, Germany, 92637
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension.
- Patients currently on IOP reducing therapy: IOP greater than or equal to 25mmHg (two IOP determinations at pre-study separated by at least one hour) OR Patients without IOP reducing therapy: IOP greater than or equal to 30mmHg (two IOP determinations at pre-study separated by at least one hour).
Exclusion Criteria:
- History of acute angle closure or closed/barely open anterior chamber angle.
- Current use of contact lenses.
- Ocular surgery or argon laser trabeculoplasty (ALT) within three months prior to pre-study visit.
- Ocular inflammation/infection occurring within three months prior to pre-study visit.
- Hypersensitivity to benzalkonium chloride or to any other component of the study drug solutions.
- Other abnormal ocular condition or symptom preventing the patient from entering the study, according to the investigator's judgement.
- Cardiac failure, sinus bradycardia, second and third degree of atrioventricular block. (The routines for prescribing topical B-blocking agents will be followed.
- Bronchial asthma, history of bronchial asthma or chronic obstructive pulmonary disease. (The routines for prescribing topical B-blocking agents will be followed).
- Pregnancy
- Women of childbearing potential who has not used adequate contraceptive methods during the last three months.
- Inability to adhere to treatment/visit plan.
- Have participated in any other clinical study within one month prior to pre-study visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Fixed combination of latanoprost 0.005% and timolol 0.5%
|
one drop in the morning and placebo in the evening
Other Names:
|
|
ACTIVE_COMPARATOR: timolol 0.5% ophthalmic solution
one drop in the morning and evening
|
one drop in the morning and evening
Other Names:
|
|
ACTIVE_COMPARATOR: latanoprost 0.005% ophthalmic solution
placebo in the morning and latanoprost .005% in the evening
|
placebo in the morning and latanoprost .005% in the evening
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To demonstrate that the fixed combination of latanoprost and timolol has a better IOP-reducing effect than the individual monotherapies.
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To examine, within treatment groups, the diurnal IOP reducing effect from baseline for all treatments at Week 26
Time Frame: 6 Months
|
6 Months
|
|
To compare the diurnal IOP reducing effect from baseline between the monotherapies latanoprost and timolol at Week 26
Time Frame: 6 Months
|
6 Months
|
|
To compare the number of treatment failures and patients withdrawn due to uncontrolled IOP from baseline to Week 26 between treatment groups
Time Frame: 6 Months
|
6 Months
|
|
To compare the proportion of patients reaching pre-specified (15, 18, and 21 mmHg) target diurnal IOPs between the treatment groups at Week 26
Time Frame: 6 Months
|
6 Months
|
|
To describe the IOP development from baseline to Week 26 for all treatment groups
Time Frame: 6 Months
|
6 Months
|
|
To compared the IOP reducing effect from baseline to Week 26 of the monotherapies with the IOP reducing effect from Week 26 to Week 52 of the fixed combination
Time Frame: 6 Months
|
6 Months
|
|
To examine, within the fixed combination treatment group, the diurnal IOP reducing effect from baseline to Week 26 and Week 52
Time Frame: 6 Months
|
6 Months
|
|
To follow the safety variables throughout the study periods.
Time Frame: 6 Months
|
6 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Glaucoma
- Glaucoma, Open-Angle
- Ocular Hypertension
- Hypertension
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Timolol
- Ophthalmic Solutions
- Pharmaceutical Solutions
- Latanoprost
Other Study ID Numbers
Other Study ID Numbers
- 96TIPG004
- A6641005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.